Neurovascular Devices – Market Insights – Japan

The Japanese neurovascular device market will see modest growth through 2035, driven by recent technological and clinical advances, including the introduction of nextgeneration devices, expanding device use in mediumvessel occlusions, and ongoing assessment of middle meningeal artery embolization for chronic subdural hematoma. Continued uptake of innovative neurovascular technologies, together with Japan’s aging population, will support growth in neurovascular procedure volumes over the forecast period.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for neurovascular devices in Japan from 2019 through 2035.

Emergence of evidence supporting use of embolization devices in the treatment of chronic subdural hematoma will support growth of neurovascular embolization procedures.

Which embolization devices will experience the highest adoption rates in the management of chronic subdural hematoma?

Which companies are positioned to gain the most in terms of market share?

What implications will the adoption of embolization procedures for chronic subdural hematoma have on the neurovascular embolization device market in Japan?

Which ongoing clinical trials will decide the treatment options for chronic subdural hematoma?

What is the expected impact of these clinical trials on overall embolization space?

New technologies in the thrombectomy device market are influencing the adoption of thrombectomy for AIS.

What new devices have entered the Japanese market in recent years, and what others are anticipated to enter the Japanese market within the forecast period?

How have market shares been shifting with the introduction of new products?

What challenges will new companies encounter in this space? Will they capture significant share from existing competitors?

What emerging technologies are currently under evaluation in clinical trials?

Flow-diverting devices and liquid embolics are contributing to growth in the neurovascular embolization device market.

How will the adoption of flow-diverting devices change the neurovascular embolization coil and coiling-assist device markets?

How will the liquid embolic market change in the coming years?

What clinical trial results are impacting the liquid embolic space?

Clinical data will play an important role in driving the adoption of neurovascular devices.

Which clinical trials were recently conducted in this market?

What is the expected impact of these clinical trials on market dynamics?